期刊文献+

冠心病患者药物洗脱支架置入术后支架内再狭窄危险因素分析 被引量:13

Risk factors of in-stent restenosis after drug-eluting stent implantation in patients with coronary atherosclerotic heart disease
下载PDF
导出
摘要 目的分析冠心病(冠状动脉粥样硬化性心脏病)患者药物洗脱支架置入术后支架内再狭窄的危险因素。方法收集2017年1月至2018年9月于南京医科大学附属南京医院行冠状动脉药物洗脱支架置入术的120例冠心病患者的临床资料,包括术后12个月随访,行经皮冠状动脉造影复查的情况,根据是否存在支架内再狭窄情况分为再狭窄组(17例)和非再狭窄组(103例)。比较2组基线资料、实验室检查指标水平、心功能情况、靶血管病变情况及置入支架情况,分析冠状动脉药物洗脱支架置入术后支架内再狭窄的危险因素。结果再狭窄组术前吸烟、术后吸烟、糖尿病、冠心病家族史比例和血清纤维蛋白原、血尿酸、胱抑素C水平以及冠状动脉Gensini积分、三支病变比例、术前狭窄程度均高于非再狭窄组,置入支架数量多于非再狭窄组[(1.9±1.1)个比(1.4±0.8)个],支架直径小于非再狭窄组,支架长度长于非再狭窄组[(30±8)mm比(24±9)mm],规律用药比例、血清总胆红素水平低于非再狭窄组[58.8%(10/17)比92.2%(95/103),(11±4)μmol/L比(15±6)μmol/L](均P<0.05)。Logistic回归分析结果表明,术前吸烟、术后吸烟、糖尿病、置入支架长度、冠心病家族史、血清胱抑素C水平均为支架内再狭窄的危险因素,规律用药和血清总胆红素水平为支架内再狭窄的保护因素(均P<0.05)。结论吸烟、糖尿病、置入支架长度、冠心病家族史和血清胱抑素C水平为支架内再狭窄的危险因素,规律用药和血清总胆红素水平为支架内再狭窄的保护因素。 Objective To analyze the risk factors of in-stent restenosis after drug-eluting stent implantation in patients with coronary atherosclerotic heart disease(CHD).Methods From January 2017 to September 2018,clinical datas of 120 patients with CHD who underwent coronary artery drug-eluting stent implantation in Nanjing First Hospital,Nanjing Medical University were collected.They were followed up for 12 months after the operation.According to whether there was restenosis in the stent,the patients were divided into restenosis group(17 cases)and non restenosis group(103 cases).The baseline data,laboratory indexes,cardiac function,target vessel disease and stent implantation were compared between the two groups,and the risk factors of restenosis after drug-eluting stent implantation were analyzed.Results The preoperative smoking,postoperative smoking,diabetes mellitus,rate of CHD family history,serum fibrinogen,blood uric acid,cystatin C levels,Gensini score of coronary artery,proportion of three vessel lesions and degree of preoperative stenosis in restenosis group were higher than those in non restenosis group(all P<0.05).The number of stents inserted was more[(1.9±1.1)vs(1.4±0.8)],stent diameter was less,stent length was longer[(30±8)mm vs(24±9)mm]in restenosis group than those in non restenosis group(all P<0.05).The proportion of regular medication and serum total bilirubin level in restenosis group were lower than those in non restenosis group[58.8%(10/17)vs 92.2%(95/103),(11±4)μmol/L vs(15±6)μmol/L](all P<0.05).Logistic regression analysis showed that preoperative smoking,postoperative smoking,diabetes,stent length,CHD family history and serum cystatin C level were risk factors for in-stent restenosis,regular medication and total bilirubin level were protective factors for in-stent restenosis(all P<0.05).Conclusion Smoking,diabetes mellitus,stent length,family history of CHD and serum cystatin C level were risk factors for in-stent restenosis,regular medication and serum total bilirubin level were protective factors for in-stent restenosis.
作者 张代民 李小波 左广锋 刘志忠 Zhang Daimin;Li Xiaobo;Zuo Guangfeng;Liu Zhizhong(Department of Cardiology,Nanjing First Hospital,Nanjing Medical University,Nanjing 210006,China)
出处 《中国医药》 2020年第11期1672-1675,共4页 China Medicine
基金 江苏省重点研发计划(BE2018611) 南京市医学科技发展项目(ZKX16048)。
关键词 冠心病(冠状动脉粥样硬化性心脏病) 药物洗脱支架 支架内再狭窄 危险因素 Coronary atherosclerotic heart disease Drug-eluting stent In-stent restenosis Risk factors
  • 相关文献

参考文献7

二级参考文献49

  • 1杨新春,张大鹏,王乐丰,徐立,葛永贵,王红石,李惟铭,倪祝华,夏昆,连勇,薛永利,马利祥.冠状动脉内应用国产替罗非班对急性ST段抬高心肌梗死急诊介入治疗后心肌灌注和临床预后的影响[J].中华心血管病杂志,2007,35(6):517-522. 被引量:73
  • 2Wang CY,Chau LY. Heme oxygenase 1 in cardiovascular dis- eases:Molecular mechanisms and clinical perspectives. Chang Gung Medical Journal,2010,33 : 13 24.
  • 3Dulak J, Deshane J, Jozkowicz A, et al. Heme oxygenase-1 and carbon monoxide in vascular pathobiology: Focus on angio- genesis. Circulation, 2008,117 : 231-241.
  • 4Wu ML, Ho YC, Yet SF. A central role of heine oxygenase-1 in cardiovascular protection. Antioxid Redox Signal, 2011,15: 1835-1846.
  • 5Ollinger R, Bilban M, Erat A, et al. Bilirubin : A natural inhibi- tor of vascular smooth muscle cell proliferation. Circulation, 2005,112 : 1030-1039.
  • 6Kuwano T, Miura S, Shirai K, et al. Serum levels of bilirubin as an independent predictor of coronary in-stent restenosis: A new look at an old molecule. J Atheroscler Thromb, 2011,18: 574-583.
  • 7Hwang HJ, Lee SW, Kim SH. Relationship between bilirubin and C reactive protein. Clin Chem Lab Med, 2011,49: 1823- 1828.
  • 8Gullu H,Erdogan D,Tok D, et al. High serum bilirubin con- centrations preserve coronary flow reserve and coronary mi- crovascular functions. Arterioscer Thromb Vasc Biol, 2005, 25 : 2289-2294.
  • 9McCarty MF. Iatrogenic Gilbert syndrome: A strategy for re- ducing vascular and cancer risk by increasing plasma uneonju- gated bilirubin. Med Hypotheses, 2007,69 : 974-994.
  • 10Abraham NG,Kappas A. Pharmacological and clinical aspects of hemo oxygenase. Pharmacol Rev, 2008,60 : 79-127.

共引文献3671

同被引文献144

引证文献13

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部